NCT07794670RecruitingPhase 2
Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease
A Phase 2b, Randomized, Double Blind, Placebo Controlled, Parallel Group Trial to Assess the Efficacy and Safety of Obicetrapib in Participants With Preclinical Alzheimer's Disease (SPINOZA Trial)
Source: ClinicalTrials.gov · Last updated 28 Sept 2026
Brief summary (registry, in English)
A study evaluating Obicetrapib in adults potentially at risk for Preclinical Alzheimer's Disease
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- First submitted
- 12 Aug 2026
- Start date
- Sept 2026
- Primary completion date
- Sept 2028
- Lead sponsor
- NewAmsterdam Pharma
- Diseases
- Alzheimer disease
- NCT number
- NCT07794670
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 400
- From Sept 2026 to the primary completion date, Sept 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- APOE genotype not meeting protocol-defined eligibility criteria
Who the study is looking for
- participants with preclinical AD
Age in the registry: 55 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| K2 Medical Research Coordinator of this site? Confirm its status | Nashville | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.